低分子肝素钙联合尿激酶治疗急性心肌梗死的效果分析

Effect analysis of low molecular weight heparin calcium combined with uro kinase in the treatment of acute myocardial infarction

目的:探讨并分析用低分子肝素钙联合尿激酶治疗急性心肌梗死(Acute myocardial infarction,AMI)的临床效果。方法:将近年来费县中医医院收治的64例AMI患者随机分为联合用药组(CM组,n=32)与尿激酶组(UK组,n=32)。对两组患者均进行常规治疗,在此基础上用低分子肝素钙对UK组患者进行治疗,用低分子肝素钙联合尿激酶对CM组患者进行治疗,然后比较两组患者的临床疗效、治疗后其胸痛的缓解时间、心电图ST段降低≥50%的时间及其不良反应的发生率。结果:CM组患者治疗的总有效率高于UK组患者,用药后其胸痛缓解的时间和心电图ST段降低≥50%的时间均短于UK组患者,P<0.05。用药后,两组患者不良反应的发生率相比,P>0.05。结论:在对AMI患者进行常规治疗的基础上,用低分子肝素钙联合尿激酶对其进行治疗能显著提高其疗效,缩短其临床症状缓解的时间,且用药的安全性较高。

Objective:To investigate the clinical efficacy of low-molecular heparin calcium in combination with urokinase in the treatment of Acute myocardial infarction(AMI).Methods:In recent years,64 patients with AMI admitted to Fei County Hospital of Traditional Chinese Medicine were randomly divided into the combined drug group(CM group,n=32)and urokinase group(UK group,n=32).To conventional treatment,two groups of patients were based on the use of low molecular heparin calcium treatment of UK group of patients,with low molecular heparin calcium combined urokinase treatment in patients with CM group,and then compare the clinical efficacy of two groups of patients,treatment of the chest pain relief time,ecg ST segment a decrease of 50%or more time and the incidence of adverse reactions.Results:The total effective rate of CM group was higher than that of UK group,and the relief time of chest pain and st-segment reduction time of ELECTROcardiogram were shorter than that of UK group(P<0.05).After treatment,the incidence of adverse reactions between the two groups was P>0.05.Conclusion:On the basis of routine treatment for AMI patients,treatment with low molecular weight heparin calcium combined with urokinase can significantly improve its efficacy,shorten the time of remission of clinical symptoms,and the safety of drug use i s higher.